RESUMEN
BACKGROUND AND AIMS: Decompensated liver cirrhosis has a poor prognosis, with a median overall survival of two to four years, which is worse than for many oncological disorders. These patients are highly susceptible to infections due to increased systemic inflammation leading to kidney failure and death. The aim was to study the efficacy of albumin in reducing episodes of decompensation, preventing bacterial infection, kidney dysfunction and mortality. METHOD: Study involved patients with Child B or C cirrhosis with an albumin level below 3.0 g/dL, who were administered 20% human albumin weekly with standard medical treatment (SMT) for three months or till serum albumin levels were 4.0 g/dL (whichever is earlier) and compared with age and sex-matched controls who received only SMT. The primary end-point was six-month mortality and the secondary end-points were reduction in infections, kidney dysfunction, ascites recurrence, hepatic encephalopathy (HE), gastrointestinal (GI) bleed and complications of cirrhosis. RESULTS: From September 2021 to January 2023, 88 cases and 86 controls were taken and followed up for six months. Overall, six-month survival was not statistically significant between groups (95.1% vs. 91.9%; p = 0·330). The incidence of recurrence of ascites (34.09% vs. 59.3%, p < 0.001), kidney dysfunction (6.8% vs. 24.4%, p < 0.001), HE (15.9% vs, 37.2%, p = 0.015), spontaneous bacterial peritonitis (SBP) (3.4% vs 17.4%, p = 0.002) and non-SBP infections (7.9% vs. 18.6%, p = 0.038) were significantly less in cases as compared with controls; however, GI bleed (14.8% vs. 17.4%, p = 0.632) was not statistically significant. CONCLUSION: Long-term human albumin acts as a disease-modifying treatment in patients with decompensated cirrhosis.
Asunto(s)
Cirrosis Hepática , Humanos , Cirrosis Hepática/complicaciones , Femenino , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Ascitis/etiología , Factores de Tiempo , Infecciones Bacterianas/etiología , Recurrencia , Albúmina Sérica/administración & dosificación , Albúmina Sérica/análisis , Anciano , Encefalopatía Hepática/etiología , Hemorragia Gastrointestinal/etiología , Adulto , Albúminas/administración & dosificación , Estudios de Casos y ControlesRESUMEN
INTRODUCTION: Spontaneous portosystemic shunts (SPSS) are frequent in liver cirrhosis and their prevalence increases as liver function deteriorates, probably as a consequence of worsening portal hypertension, but without achieving an effective protection against cirrhosis complications. This study was conducted to detect the prevalence of portosystemic shunts in liver cirrhosis patients and analyze its prognostic role. METHOD: We conducted a prospective observational study, where 92 patients with decompensated cirrhosis were evaluated based on history, physical examination, biochemical tests and abdominal computed tomography (CT) angiography findings. A follow-up was done after six months for the development of cirrhosis-related complications. RESULTS: Of the 92 cirrhotic patients, 57.6% had SPSS (large SPSS + small SPSS) detected by multi-detector computed tomographic angiography. Overall, we found large SPSS in 24 (26.1%) patients, small SPSS in 29 (31.5%) patients and no shunt in 39 (42.4%) patients. Among the shunts, the splenorenal shunt is the most frequent type (25, 27.2%) followed by the paraumbilical shunt (20.7%). Previous decompensating events, including hepatic encephalopathy, ascites, spontaneous bacterial peritonitis and gastrointestinal bleed, were experienced more frequently by the large SPSS group followed by the small SPSS and without SPSS groups. Regarding follow-up, decompensating episodes of hepatic encephalopathy developed more frequently in patients with large SPSS (41.7%) than in patients with small SPSS (24.1%) followed by patients without SPSS (12.8%). CONCLUSION: In summary, all cirrhotic patients should be studied with radiological imaging to detect the presence of portosystemic shunts. In several cases, patients with large SPSS had a more impaired liver function and more frequent complications of portal hypertension. So, these patients would probably benefit from a closer surveillance and more intensive therapy.
Asunto(s)
Várices Esofágicas y Gástricas , Encefalopatía Hepática , Hipertensión Portal , Derivación Portosistémica Intrahepática Transyugular , Humanos , Encefalopatía Hepática/epidemiología , Encefalopatía Hepática/etiología , Derivación Portosistémica Intrahepática Transyugular/efectos adversos , Pronóstico , Prevalencia , Hipertensión Portal/etiología , Hipertensión Portal/complicaciones , Cirrosis Hepática/complicaciones , Cirrosis Hepática/epidemiología , Várices Esofágicas y Gástricas/etiología , Várices Esofágicas y Gástricas/complicacionesAsunto(s)
Hepatitis , Complicaciones Infecciosas del Embarazo , Embarazo , Femenino , Humanos , Virus de la Hepatitis B/genética , Antivirales/uso terapéutico , Transmisión Vertical de Enfermedad Infecciosa , Complicaciones Infecciosas del Embarazo/tratamiento farmacológico , ADN Viral , Carga ViralRESUMEN
Big data has been a topic of interest for many researchers and industries for the past few decades. Due to the exponential growth of technology, a tremendous amount of data is generated every minute. This article provides a strategic review of big data in the healthcare sector. In particular, this article highlights various applications and issues faced by the healthcare industry using big data by evaluating various journal articles between 2016 and 2021. Multiple issues related to data mining, storing, analyzing, and sharing of big data in healthcare, briefly summarizing deep-learning-based tools available for big data analytics, have been covered in this article. This article aims to benefit the research community by summarizing various research tools and processes available today to manage big data in healthcare.